1
Taxiarchis Botsis1,2 & Robert Ball1
1Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration
2Department of Computer Science, University of Tromsø, Tromsø, Norway
MIE 2011 Oslo, Norway
Network analysis of possible anaphylaxis cases reported to the US - - PowerPoint PPT Presentation
Network analysis of possible anaphylaxis cases reported to the US Vaccine Adverse Event Reporting System after H1N1 influenza vaccine Taxiarchis Botsis 1,2 & Robert Ball 1 1 Center for Biologics Evaluation and Research (CBER), U.S. Food and
1
Taxiarchis Botsis1,2 & Robert Ball1
1Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration
2Department of Computer Science, University of Tromsø, Tromsø, Norway
MIE 2011 Oslo, Norway
2
n VAERS stores adverse events (AEs)
n health care providers n vaccine recipients n manufacturers
n Well-trained nurses code these reports:
n using the Medical Dictionary for Regulatory
n assign preferred terms (PTs) that represent
3
n Identify patterns and n Detect safety signals
4
n
n
n
n
5
Report_1= [VAX1 VAX2 PT1 PT2 PT3] decomposed to combinations of: VAX1-PT1, VAX1-PT2, VAX1-PT3, VAX2- PT1, VAX2- PT2, VAX2- PT3 And
VAX1-VAX2
And PT1- PT2, PT1- PT3, PT2-PT3
Report_1+ Report_2+…+ Report_n
PT1 PT2 PT3 VAX1 VAX2 VAX1 16 33 5 50 VAX2 4 10 5 50 PT1 12 10 16 4 PT2 12 9 33 10 PT3 10 9 5 5 VAX1, VAX2: Vaccines PT1, PT2, PT3: MedDRA Preferred Terms (PT) representing adverse events
# reports containing this tie
6
n Nodes the PTs and vaccines n Edges their interconnections n Edge weight the number of occurrences
7
n identifies all the maximal islands within a
n triangular weight – TW (= number of triangles
n TWs emphasize multiple interactions, filter out
* M. Zaversnik and V. Batagelj, Islands, Sunbelt XXIV, 2004.
8
N=301 nodes What a mess!
9
It is clear now!
N=30 nodes
Brighton Collaboration Criteria
10
n Network analysis identifies patterns related to adverse
n Limitations:
n Statistical framework of network analysis n Retrospectively collected dataset
n Future goals:
n Evaluation of other approaches for network reduction and n Application to prospectively collected data for prediction
immunization reported to VAERS? Clinical Pharmacology & Therapeutics. 2011 Aug;90(2):271-8.
11
n We thank the Medical Officers at FDA
n Research Participation Program,